A chronological record of peer-reviewed Retatrutide research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Peptide research timelines are often misrepresented online. Claims about "how quickly Retatrutideworks" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.
Primary mechanism studied: Triple GIP/GLP-1/Glucagon Agonism. Primary indications investigated: Weight management, Type 2 diabetes, NASH/MASLD.
Phase 3 trial evaluating retatrutide (10, 15mg) versus placebo in NASH patients with fibrosis, measuring liver histology and fibrosis regression over 52 weeks.
Phase 3 trial evaluating retatrutide versus placebo for knee osteoarthritis in obese subjects, measuring WOMAC scores, joint space narrowing, and pain reduction.
Genome-wide association study of retatrutide responders (>20% weight loss) versus non-responders to identify genetic variants predicting treatment response.
Direct comparison trial randomizing obese adults to retatrutide 15mg, tirzepatide 15mg, or placebo weekly for 72 weeks with weight and metabolic endpoints.
Phase 3 trial evaluating weekly subcutaneous retatrutide for weight loss in adults with obesity, comparing four dose levels (2.5, 5, 10, 15mg) to placebo over 72 weeks.
Phase 3 trial evaluating retatrutide efficacy and safety in patients with type 2 diabetes and obesity over 68 weeks with dose escalation protocol.
Mechanistic substudy using MRI to characterize changes in visceral fat, subcutaneous fat, and muscle mass with retatrutide versus placebo.
Analysis of biomarkers in retatrutide trials showing effects on systolic/diastolic BP, lipid profile, and inflammatory markers, with partial independence from weight loss.
fMRI study examining neural responses to food images and appetite-related questionnaires in obese subjects receiving retatrutide versus placebo.
Follow-up study examining durability of metabolic improvements 12 weeks after discontinuation of retatrutide in diabetes patients.
Comprehensive safety analysis of retatrutide trials examining amylase, lipase, calcitonin, pancreatic imaging, and pancreatitis incidence across 72-week treatment duration.
Mechanistic animal study examining the neural and receptor mechanisms underlying GLP-1-mediated nausea and gastric dysmotility with retatrutide.
Hormonal analysis substudy measuring fasting and postprandial levels of ghrelin, PYY, CCK, leptin, and adiponectin throughout the retatrutide trial.
Mechanistic substudy examining vascular endothelial function (FMD), arterial stiffness (PWV), and inflammatory biomarkers (CRP, IL-6, TNF-α) with retatrutide.
Phase 2 trial showing retatrutide produced up to 24.2% body weight loss at 48 weeks, surpassing tirzepatide results.
Mechanistic study in rodent obesity models examining the relative contribution of each agonist (GLP-1, GIP, glucagon) to retatrutide-mediated weight loss using selective antagonists.
Phase 1 study characterizing tolerability of once-weekly retatrutide in healthy volunteers with dose escalation from 0.5 to 15mg over 12 weeks.
Cell-based mechanistic studies comparing retatrutide, tirzepatide, and semaglutide effects on hepatic glucose production and thermogenic gene expression via glucagon signaling.
Mechanistic substudy using 24-hour indirect calorimetry to measure changes in resting metabolic rate, activity thermogenesis, and diet-induced thermogenesis.
The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for Retatrutide is L4 (Strong Clinical Evidence): multiple controlled human clinical trials with replicable data. Treat each study as one data point, not a conclusion.
PeptideMark indexes 31 studies on Retatrutide: 8 human studies, 12 animal studies, 5 in-vitro, and 6 reviews. The current evidence level is L4 — strong clinical evidence.
The earliest indexed peer-reviewed study on Retatrutide in the PeptideMark library was published in 2023 (New England Journal of Medicine). Research activity has continued through 2025.
Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.
Yes. Recent publications on Retatrutide appear as recently as 2025, indicating ongoing investigation. See the research log on this page for the specific study.
Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.